| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD7-H522b | Human | Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) |  |
|
|
| CD7-M5252 | Mouse | Mouse CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD7-H5257 | Human | Human CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD7-C5259 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| TN7-H82F6 | Human | Biotinylated Human CD27 / TNFRSF7 Protein, Fc,Avitag™ |  |
|
|
| CD7-H5254 | Human | Human CD27 / TNFRSF7 Protein, Fc Tag (HPLC verified) |  |
|
|
Flow Cytometry assay shows that Human CD27, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD7-H5257) can bind to Raji cells Surface Human CD70. The concentration of CD27 used is 10 μg/mL (Routinely tested).
Immobilized Mouse CD27, Mouse IgG2a Fc Tag (Cat. No. CD7-M5252) at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse CD70, His Tag, Avi Tag with a linear range of 1-16 ng/mL (QC tested).
The purity of Human CD27, His Tag (Cat. No. CD7-H522b) is more than 85% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CD27 monoclonal antibody (Aduro Biotech) | BION-1402 | Phase 1 Clinical | Aduro Biotech | Neoplasms | Details |
| Varlilumab | CDX-1127 | Phase 2 Clinical | Celldex Therapeutics | Urologic Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Urogenital Neoplasms; Lymphoma; Glioma; Lymphoma, Non-Hodgkin; Urologic Neoplasms; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Kidney Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Solid tumours | Details |
| MK-5890 | MK-5890 | Phase 2 Clinical | Merck & Co Inc | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
